To evaluate the immunologic factors that contribute to protection against Mycobacterium avium complex (MAC), cytokine production by peripheral blood mononuclear cells (PBMC) from human immunodeficiency virus-negative persons with pulmonary MAC (MAC patients) and healthy control subjects with a delayed hypersensitivity skin test response to M. avium sensitin (MAS-positive control subjects) was measured. In MAC patients, mycobacteriumstimulated PBMC produced higher concentrations of interleukin (IL)-10 but lower concentrations of interferon (IFN)-g, IL-12, and tumor necrosis factor (TNF)-a, compared with PBMC from MAS-positive control subjects. Immunolabeling for intracellular IL-10 revealed that this cytokine was produced by both monocytes and T cells. Alveolar macrophages produced TNF-a and IL-10 in response to MAC, which suggests that these cytokines are produced in the lungs of patients with pulmonary disease caused by this pathogen. Our findings suggest that IFN-g, TNF-a, and IL-12 contribute to protection against MAC, whereas IL-10 is immunosuppressive.
infection, in whom it causes disseminated disease involving multiple organs [3, 4] . Because patients with advanced HIV infection have multiple abnormalities in numbers and functions of T cells, the specific immunologic defects that predispose to disease from M. avium remain undefined. The nature of immune dysfunction that predisposes to MAC lung disease in HIVnegative persons is also unknown. Understanding these defects is important to the development of immunotherapeutic modalities to treat and prevent disease due to MAC in persons with or without HIV infection.
To gain insight into the immunologic factors that contribute to protection against MAC, we studied healthy persons who were infected with MAC and HIV-negative persons with pulmonary disease due to these organisms. We reasoned that healthy infected persons mount an effective immune response to MAC, whereas persons with pulmonary disease do not. We evaluated the immune response in these 2 groups by comparing the capacity of peripheral blood mononuclear cells (PBMC) to proliferate and produce cytokines in response to MAC.
Materials and Methods
Study population. Blood was obtained from 26 patients with a diagnosis of pulmonary disease due to MAC (MAC patients). A diagnosis was made on the basis of guidelines recommended by the American Thoracic Society [5] . In all cases, sputum culture results were positive, chest abnormalities were present on radiographs, and disease was confined to the lungs. Of the 26 patients, 9 had cavitary disease and 17 had nodular bronchiectasis. None of the patients had risk factors for HIV infection. Twenty-one pa-tients were women and 5 were men, and they had a median age of 69 years (range, 39-85 years). At the time that blood samples were obtained, 10 patients had received no treatment and 16 had been treated for 1-21 months with antimycobacterial agents.
Skin testing was done on healthy control subjects to evaluate the delayed-type hypersensitivity response to M. avium sensitin and tuberculin, as described elsewhere [6, 7] . The M. avium sensitin 10/ 2 (filling lot 68; provided by Kaare Haslov, Statens Serum Institute, Copenhagen). We excluded from the study persons in whom the tuberculin skin test reaction was у5 mm and persons in whom the M. avium sensitin skin test response was 1-9 mm. The remaining subjects were divided into those with positive (у10 mm in diameter) or negative (0 mm in diameter) M. avium skin test results. Blood was obtained from 19 healthy control subjects who had positive M. avium skin test responses (median diameter, 21 mm; range, 11-35 mm) and from 3 persons with negative skin test responses. These groups are hereafter referred to as MAS-positive and MASnegative control subjects, respectively. Bronchoalveolar lavage (BAL) fluid was obtained from 8 patients who underwent bronchoscopy to evaluate the possibility of cancer. None of these patients had clinical or laboratory evidence of tuberculosis, MAC disease, or HIV infection. In all cases, the pathologic process was unilateral, and BAL was done in lungs with no bronchoscopic or radiographic evidence of cancer.
Isolation of PBMC and CD14 ϩ monocytes. PBMC were isolated from blood by differential centrifugation over Ficoll-Paque (Pharmacia). PBMC were centrifuged on a Percoll gradient (Amersham Pharmacia Biotech), and purified CD14 ϩ cells were isolated from the monocyte fraction by positive selection with magnetic beads conjugated to anti-CD14 (Miltenyi Biotech Immunolabeling of intracellular cytokines. Immunolabeling to detect intracellular TNF-a, IL-10, and IFN-g was done by using the Cytofix/Cytoperm Plus kit (PharMingen). Controls for each experiment included cells that were unstained, cells to which fluorescein isothiocyanate (FITC)-conjugated or phycoerythrin (PE)-conjugated mouse IgG had been added, and cells that had been subjected to single staining either with the antibody to the surface marker or to the cytokine being evaluated.
PBMC or macrophages were cultured with heat-killed MAC for 1 day to detect intracellular TNF-a and IL-10 and for 4 days to detect intracellular IFN-g. To induce intracellular accumulation of newly synthesized proteins, 0.7 mL/mL Golgi Stop (PharMingen) was added for 6 h to the cells in culture. Cells were then harvested, and immunolabeling was performed. For double staining, anti-CD3 (FITC; Dako) or PE-cyanine 5-conjugated (PC5; Immunotech), anti-CD4 (PE; Dako), anti-CD8 (PE; Dako), or anti-CD14 (PC5 or PE; Becton Dickinson) were first added. After being washed with PBS and 5% fetal calf serum (FCS), cells were fixed in Cytofix/Cytoperm and were washed twice in 1ϫ permeabilization/wash solution. FITC anti-TNF-a, PE anti-IL-10, or PE anti-IFN-g (all from PharMingen) were then added in staining buffer and 1ϫ permeabilization/wash solution. After incubation at 40ЊC for 40 min, cells were washed in PBS and 5% FCS and were analyzed by flow cytometry, using a fluorescence-activated cell sorter (EPICS C; Coulter).
Statistical analysis. Data are shown as the . Difmean ‫ע‬ SE ferences between groups were compared by use of the unpaired Student's t test.
Results

Proliferative responses to MAC.
In preliminary experiments, we determined that M. avium strain 104 and M. intracellulare strain 1067 elicited similar proliferative responses by PBMC from MAS-positive control subjects and from MAC patients. We selected the M. intracellulare strain for use in subsequent experiments. To determine the capacity of T cells to recognize mycobacterial antigens, we measured proliferative responses of PBMC to killed MAC and to M. tuberculosis. The proliferative response of PBMC from 22 MAC patients was ; figure 1) . The proliferative response of PBMC P p .07 from MAC patients to M. tuberculosis was also about half that of PBMC from MAS-positive control subjects ( ; figure P p .01 1). Because MAS-positive control subjects had negative tuberculin skin test results and were unlikely to be infected with M. tuberculosis, proliferation to M. tuberculosis probably resulted from the recognition of antigens common to both mycobacteria. The negative tuberculin test results suggest that a proliferative response by peripheral blood lymphocytes is not sufficient for delayed-type hypersensitivity, which may require other factors that permit lymphocytes to home to tissue sites where tuberculin is present. MAS-negative control subjects showed minimal proliferation to MAC (mean counts per minute, ), which suggests that proliferative responses 2389 ‫ע‬ 706 reflected the response of T cells sensitized by prior exposure to MAC.
Cytokine production by PBMC from patients and control subjects. Because IFN-g contributes to host defenses against M. tuberculosis and M. avium in animals [8] [9] [10] , we evaluated the capacity of PBMC to produce this cytokine after stimulation with MAC. PBMC from 19 MAC patients produced 541 ‫ע‬ pg/mL of IFN-g, whereas PBMC from 15 MAS-positive 155 control subjects produced pg/mL ( ; figure 1644 ‫ע‬ 305 P p .003 2A). PBMC from MAS-negative control subjects produced only pg/mL of IFN-g, which suggests that IFN-g secretion 115 ‫ע‬ 23 depended on T cells sensitized by prior infection with MAC. IL-4 was not detected in supernatants of PBMC from MAC patients or from MAS-positive control subjects.
Because studies in animals have shown that TNF-a is essential for host defense against M. tuberculosis and M. avium [11, 12] , whereas IL-10 is immunosuppressive [13] [14] [15] , we evaluated the capacity of PBMC to produce these cytokines in response to MAC. PBMC from MAC patients produced lower TNF-a concentrations than did those from MAS-positive control subjects ( vs. pg/mL; ). In con-269 ‫ע‬ 20 794 ‫ע‬ 15 P p .006 trast, PBMC from MAC patients produced higher concentrations of IL-10 than did those from MAS-positive control subjects ( vs. pg/mL; ). 1559 ‫ע‬ 485 432 ‫ע‬ 73 P p .03 Production of IFN-g, TNF-a, and IL-10 by PBMC from MAC patients with cavitary disease and those with nodular bronchiectasis were not significantly different (data not shown).
IL-12 and IL-18 are produced by monocytes and contribute to production of IFN-g by T cells and NK cells [16] . To determine whether the reduced IFN-g production by MAC patients was due to reduced production of IL-12 and IL-18, we measured the capacity of PBMC to produce these cytokines (figure 2B). PBMC from 10 MAC patients produced lower concentrations of IL-12 than did PBMC from MAS-positive control subjects ( vs. pg/mL; ϩ and CD8 ϩ cells that were IFN-g positive were higher in MAS-positive control subjects, these differences were not statistically significant, probably because of the small number of subjects tested.
Cellular sources of TNF-a and IL-10. When PBMC are stimulated with M. tuberculosis, monocytes are the major source of TNF-a and IL-10 [17, 18] . However, some mycobacterial antigens can elicit production of these cytokines from T cells [19, 20] . To identify the source of these cytokines in PBMC stimulated with MAC, we combined surface immunolabeling with staining to detect intracellular cytokines in cells from 5 MAS-positive control subjects and 3 MAC patients. For each experiment, PBMC were divided into 2 aliquots. One aliquot was cultured with MAC for 24 h, and single and double immunolabeling were performed by using anti-CD3, anti-TNF- a, and anti-IL-10. A second aliquot of PBMC was centrifuged over Percoll, and CD14 ϩ monocytes were isolated by positive selection with magnetic beads conjugated to anti-CD14. These monocytes, which were 190% CD14 ϩ by flow cytometry, were cultured with MAC for 24 h, and immunolabeling was performed as for PBMC, except that anti-CD14 was substituted for anti-CD3.
Single staining with anti-TNF-a revealed that the percentage of cells expressing intracellular cytokine was 10- Ϫ cells. Figure 3 shows a representative result. These findings confirm the results of single immunolabeling, demonstrating that higher percentages of monocytes than of T cells expressed intracellular TNF-a and IL-10. However, because the percentage of T cells in PBMC is higher than that of monocytes, both cell populations contribute significantly to production of these cytokines.
Cytokine production by alveolar macrophages. Because MAC causes lung disease in immunocompetent persons, we wished to determine whether the cytokines produced by blood monocytes were produced by alveolar macrophages. We obtained alveolar macrophages from 8 persons without mycobacterial disease and cultured them in the presence or absence of heat-killed MAC. Minimal amounts of TNF-a and IL-10 were produced in the absence of MAC. However, TNF-a concentrations were markedly elevated (mean levels, pg/mL) in supernatants 2698 ‫ע‬ 364 of MAC-stimulated macrophages from all patients (figure 4). IL-10 concentrations were also high (mean level, 2550 ‫ע‬ 490 pg/mL) in supernatants of macrophages from 6 patients. These findings demonstrate that TNF-a and IL-10 are likely to be produced in the lungs of MAC patients.
Discussion
MAC causes disseminated disease in patients with HIV infection and pulmonary disease in persons without obvious immunodeficiency. Although many studies have evaluated the immune response to MAC infection in animals, limited data are available for humans. M. avium sensitin is a valuable tool to evaluate prior infection with MAC in healthy individuals. Persons with skin test responses to this sensitin are likely, for sev- eral reasons, to have been previously infected with MAC. First, patients with culture-proven MAC pulmonary disease show selective skin test reactivity to M. avium sensitin [7] . Second, PBMC from MAS-positive control subjects proliferated and produced IFN-g in response to MAC, whereas PBMC from MAS-negative control subjects did not, which suggests that T cells sensitized to MAC antigens were only present in MASpositive control subjects. Third, skin test reactions to mycobacterial preparations, such as tuberculin and lepromin, are considered to be evidence of infection with M. tuberculosis and M. leprae, respectively.
The current study represents the first evaluation of cytokine production in immunocompetent persons with pulmonary MAC disease and in healthy control subjects with MAC infection. In MAC patients, mycobacterium-stimulated PBMC (compared with PBMC from MAS-positive control subjects) produced higher concentrations of IL-10 but lower concentrations of IFNg, IL-12, and TNF-a. The percentages of CD4 ϩ and CD8 ϩ T cells producing IFN-g were reduced in MAC patients, and IL-10 was produced by both monocytes and T cells. Alveolar macrophages produced TNF-a and IL-10 in response to MAC, suggesting that these cytokines are produced in the lungs of patients with pulmonary disease from this pathogen. Our findings suggest that IFN-g, TNF-a, and IL-12 contribute to protection against MAC, whereas IL-10 is immunosuppressive.
In the immune response to mycobacterial infection, macrophages contribute to host defenses and to limiting the inflammatory response through secretion of proinflammatory cytokines, such as TNF-a, and anti-inflammatory cytokines, such as IL-10. TNF-a is essential for the development of protective immunity against tuberculosis and MAC in mice: animals with disrupted genes for TNF-a or the 55-kDa TNF-a receptor show marked susceptibility to tuberculosis [11] and develop fatal MAC infection [12] . In addition, recombinant TNF-a reduces growth of MAC in mice [21] . Unlike TNF-a, IL-10 inhibits antimycobacterial defenses: mice lacking the IL-10 gene have lower bacterial burdens of M. bovis bacille Calmette-Guérin [13] , and anti-IL-10 antibodies enhance resistance to MAC [14, 15] .
In the immune response to M. tuberculosis in humans, TNFa is a double-edged sword. TNF-a contributes to the capacity of alveolar macrophages to inhibit growth of M. tuberculosis [22] , perhaps by inducing apoptosis [23] . However, TNF-a production by monocytes is higher in tuberculosis patients than in healthy control subjects [24, 25] , and increased TNF-a production is associated with fever and cachexia in tuberculosis patients [24] . IL-10 production by PBMC in tuberculosis patients is variable-some investigators have reported increased production [26] and others have not [18, 27] . Our current findings in MAC infection differ significantly from those in human tuberculosis. We demonstrated predominant production of IL-10 over TNF-a by PBMC from MAC patients, a finding that is consistent with the protective role of TNF-a and the immunosuppressive role of IL-10 in murine models. Reduced TNF-a production in MAC patients, compared with tuberculosis patients, is consistent with the clinical manifestations of these infections, with MAC disease being more slowly progressive and having less prominent fever and weight loss.
IFN-g plays a pivotal role in immune defenses against mycobacteria, and IL-12 is a major stimulus for IFN-g production [28, 29] . Mice lacking IFN-g or IL-12 due to targeted gene deletions have increased susceptibility to M. tuberculosis [8, 9, 30] and to MAC [10, 31] . Administration of IL-12 confers protection to animals infected with MAC, and protection is dependent on production of IFN-g [10] . Most studies of the role of IFN-g and IL-12 in immune defenses against nontuberculous mycobacteria in humans involved kindreds with rare genetic susceptibility to severe extrapulmonary and disseminated mycobacterial disease. For example, genetic defects that cause reduced IL-12 production by monocytes or defective expression of receptors for IFN-g or IL-12 predispose to severe manifestations of mycobacterial disease [32] [33] [34] [35] [36] . In addition, administration of IFN-g ameliorated disease in small numbers of patients with multidrug-resistant tuberculosis [37] and disseminated and pulmonary MAC disease [38, 39] .
Our current results confirm and extend these observations, demonstrating that IFN-g and IL-12 contribute to protection against MAC in persons without evident immunodeficiency. Production of IFN-g and IL-12 by PBMC from MAC patients was reduced by 70% and 85%, respectively, compared with findings in MAS-positive control subjects. The percentages of CD4 ϩ and CD8
ϩ cells in MAC-stimulated PBMC were similar in patients and control subjects, suggesting that reduced T cell numbers did not explain decreased IFN-g production. However, it To account for reduced production of TNF-a, IL-12, and IFN-g by PBMC from MAC patients, we speculate that the primary abnormality in these individuals is excessive production of IL-10, which can exhibit multiple immunosuppressive effects. First, IL-10 inhibits the capacity of M. avium-infected monocytes to produce TNF-a, reducing apoptosis and enhancing mycobacterial survival [40, 41] . Second, IL-10 inhibits IL-12 production by monocytes exposed to mycobacteria [42, 43] , and reduced IL-12 production leads to decreased IFN-g secretion. Third, IL-10 directly down-regulates expression of costimulatory molecules on mycobacterium-infected monocytes, inhibiting IFN-g production by T cells [44] . Enhanced IL-10 production in MAC patients parallels findings in patients with lepromatous leprosy and ineffective immunity to M. leprae [45, 46] . However, IL-4 production is also increased in lepromatous leprosy, but not in MAC patients. Transforming growth factor-b reduces IFN-g production in tuberculosis patients [26] , and further studies should evaluate the contribution of this cytokine to the abnormalities observed in MAC patients.
Mycobacterial antigens are potent stimuli for IL-10 production. CD14 ϩ monocytes are the major source of IL-10 produced by PBMC in response to M. tuberculosis and M. leprae [18, 46] , and IL-10 mRNA is detected predominantly in CD14 ϩ
CD3
Ϫ cells in the pleural fluid of patients with tuberculous pleuritis [47] . However, mycobacterium-reactive T cells from patients with tuberculosis or leprosy, when cultured in vitro, can also produce IL-10 [20, 48, 49] . We found that MAC elicited IL-10 production by both monocytes and T cells. Although the percentage of IL-10-containing cells was 10-fold higher in monocytes than in T cells, the number of T cells in PBMC is 5-10-fold higher than that of monocytes, so that both cell populations are likely to contribute significantly to IL-10 production. Our findings differ from those of Mü ller et al. [50] , who reported that monocytes were the major source of IL-10 when PBMC from healthy control subjects and HIV-infected patients were stimulated with MAC. These subjects were not tested for MAC infection, and only 1 HIV-infected patient had MAC disease. In immunocompetent MAC patients and MAS-positive control subjects, sensitized T cells may contribute significantly to IL-10 production. In contrast, immunocompetent persons who are not infected with MAC and HIV-infected persons with defective T cell function may lack sensitized T cells that produce IL-10.
In summary, we found that, in MAC patients, mycobacterium-stimulated PBMC produced more IL-10 but less IFN-g, IL-12, and TNF-a than did PBMC from MAS-positive control subjects. This pattern of cytokine production differs from those previously described for patients with other mycobacterial infections, such as tuberculosis and leprosy. We speculate that excessive IL-10 production inhibits secretion of TNF-a, IL-12, and IFN-g, increasing susceptibility to development of pulmonary disease from MAC. Understanding the mechanisms responsible for increased IL-10 production may facilitate the development of immunomodulatory strategies to treat and prevent disease due to MAC.
